Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...

FDA IND clearance enables a phase 3 program evaluating TRIESENCE for postoperative ocular inflammation and pain following cataract surgery, aiming to broaden on-label use beyond current intraocular ...

Arun Menawat, Chairman & CEO, emphasized the completion of recruitment for CAPTAIN, the first multicenter, randomized, controlled trial comparing a new technology to robotic radical prostatectomy, ...

A randomized trial of hospitalized patients with moderate hyponatremia compared targeted sodium correction versus routine care on mortality and rehospitalization rates.

The planned Phase 3 study is a randomized, placebo-controlled, double-masked, multicenter clinical trial designed to evaluate the safety and efficacy of TRIESENCE in patients undergoing cataract ...

Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms emerged, according to a new study.

The MarketWatch News Department was not involved in the creation of this content. TIGERTRIEVER(TM) 13 is the first device shown to meet safety and effectiveness endpoints for restoring blood flow in ...

The Voro Urologic Scaffold shows promise in reducing stress urinary incontinence post-prostatectomy, with improved continence rates when optimally placed. Interim results from the ARID trial revealed ...

Results from a large randomized trial found that a midpregnancy blood test paired with targeted interventions improved neonatal outcomes in low-risk pregnancies. Screen-guided care using a maternal ...

Patients with intermediate-high risk pulmonary embolism (PE) have an elevated right ventricular (RV) to left ventricular (LV) diameter ratio and are at risk of early clinical decompensation and ...